Debate Over ApoB Testing Versus Standard Cholesterol Tests

Current Cholesterol Testing Practices

A recent article examines the potential shift from traditional cholesterol tests to apolipoprotein B (apoB) tests for assessing cardiovascular disease risk. Standard cholesterol panels typically evaluate HDL (high-density lipoprotein) and LDL (low-density lipoprotein) cholesterol levels. Emerging research indicates that alternative cholesterol markers, like apoB, may serve as more accurate indicators of cardiovascular disease susceptibility.

Advocacy for ApoB Testing

An article published in Science highlights the increasing support for apoB testing, as opposed to conventional cholesterol assessments. Dr. Sniderman, a cardiologist at McGill University, advocates for routine apoB tests, which can be performed for as little as $20. He argues that these tests could identify millions more patients who would benefit from cholesterol-lowering therapies, thereby minimizing unnecessary treatments. Furthermore, apoB tests have the potential to detect individuals at risk of heart attacks, a group that standard cholesterol tests often overlook. A 2009 study revealed that 50% of patients hospitalized for heart attacks exhibited normal or low LDL cholesterol levels.

Research Findings on ApoB Levels

Dr. Sniderman and his colleagues have extensively researched the significance of the apoB protein. Their recent studies reaffirm the critical role of measuring apoB. One investigation compared individuals with varying apoB levels but identical LDL cholesterol readings, underscoring the necessity of assessing this protein. According to their findings, U.S. patients with elevated apoB levels are projected to experience nearly three million additional cardiovascular disease events over the next 15 years compared to those with normal apoB levels.

Contrasting Opinions and Challenges

Despite these findings, the discussion around apoB testing remains contentious. Dr. Scott Grundy argues that existing evidence does not significantly support apoB as a superior predictor over LDL cholesterol. Additionally, altering clinical guidelines and standard practices is a gradual process. Proponents of apoB testing acknowledge that while LDL remains an effective test 85% of the time, there is a desire to enhance its predictive accuracy for safer outcomes. Researchers concur that while LDL levels are important, the future may necessitate more precise and personalized assessments, such as apoB testing.

Conclusion

The conversation surrounding the adoption of apoB tests underscores a critical evolution in cardiovascular risk assessment. As research continues to evolve, the medical community may need to reconsider established testing protocols to improve patient outcomes.

Reference

Leslie, Mitch. (2017, December 15th). Is it time to retire cholesterol tests? Retrieved from: http://www.sciencemag.org/news/2017/12/it-time-retire-cholesterol-tests doi:10.1126/science.aar6854